

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Info	rmation						
1. Given Name (First Name) Jean-Frederic	2. Surname (Last Name) 3. Date Colombel 07-December-2016						
4. Are you the corresponding author?	✓ Yes No	✓ Yes No					
5. Manuscript Title 2018-2019 ECCO Annual Disclosure o	of Potential Conflicts of	Interest					
6. Manuscript Identifying Number (if you	u know it)						
Section 2. The Work Under	· Consideration for P	ublication					
Did you or your institution at any time re any aspect of the submitted work (include statistical analysis, etc.)? Are there any relevant conflicts of int	ling but not limited to grar						
Section 3. Relevant financi	al activities outside	the submitted	work.				
Place a check in the appropriate box of compensation) with entities as de- clicking the "Add +" box. You should Are there any relevant conflicts of int If yes, please fill out the appropriate	scribed in the instruction report relationships that terest? Yes	ns. Use one line fo	or each ent	ity; add as many lines as you n	eed by		
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments			
AbbVie	✓			Consultant, Speaker			
Janssen Pharmaceuticals	✓			Consultant			
Takeda	✓			Consultant, Speaker			
Amgen			√	Consultant			
Boehringer-Ingelheim			√	Consultant			
Celgene Corporation			√	Consultant, Speaker			
Celltrion			√	Consultant			
Enterome			√	Consultant			



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Ferring Pharmaceuticals				√	Consultancy, Speaker
Genentech				✓	Consultant
Medimmune				✓	Consultant
Merck & Co.				√	Consultant
Pfizer				✓	Consultant
Protagonist				√	Consultant
Second Genome				✓	Consultant
Seres Therapeutics				√	Consultant
Shire				√	Consultant
Takeda				√	Consultant
Theradiag				✓	Consultant
Theravance Biopharma				√	Consultant
Eli Lilly				√	Consultant
Intestinal Biotech Development				✓	Shareholder
Genfit				✓	Shareholder
Nextbiotix				✓	Consultant
Novartis Pharmaceuticals				✓	Consultant
Otsuka American Pharmaceutical				✓	Consultant
Arena Pharmaceutical				✓	Consultant
Nextbiotix				✓	Consultant
Gilead				✓	Consultant
Zealand Pharmaceutical				✓	Consultant

Section 4.	Intellectual Property Patents & Copyrights	
Do you have ar	y patents, whether planned, pending or issued, broadly relevant to the work?	✓ No



Section 5.	Relationships not covered above			
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?			
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):			
No other relationships/conditions/circumstances that present a potential conflict of interest				
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.			
Section 6.	Disclosure Statement			
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box			

Dr. Colombel reports grants from AbbVie, grants from Janssen Pharmaceuticals, grants from Takeda, other from Amgen, other from Boehringer-Ingelheim, other from Celgene Corporation, other from Celltrion, other from Enterome, other from Ferring Pharmaceuticals, other from Genentech, other from Medimmune, other from Merck & Co., other from Pfizer, other from Protagonist, other from Second Genome, other from Seres Therapeutics, other from Shire, other from Takeda, other from Theradiag, other from Theravance Biopharma, other from Eli Lilly, other from Intestinal Biotech Development, other from Genfit, other from Nextbiotix, other from Novartis Pharmaceuticals, other from Otsuka American Pharmaceutical, other from Arena Pharmaceutical, other from Nextbiotix, other from Gilead, other from Zealand Pharmaceutical, outside the submitted work;

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.